PHA-543613 is a potent and selective α7 nicotinic acetylcholine receptor (α7 nAChR) agonist; it is a potential therapeutic agent for cognitive deficits in schizophrenia and Alzheimer's disease; active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays.